GlaxoSmithKline plc (ADR) (NYSE:GSK)

CAPS Rating: 4 out of 5

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Recs

1
Player Avatar cllqmb (< 20) Submitted: 3/12/2011 10:38:11 PM : Outperform Start Price: $36.12 GSK Score: +20.95

FDA approval of BENLYSTA will bring profits from US markets and European approval is on the way later this year. Revenues are going to increase immensely over the next few years and unless there is a drug approval that will compete with the current monopolistic standing of this new drug, both Human Genome and Glaxosmithkline will do extremely well.

Featured Broker Partners


Advertisement